Related Experiment Video
Updated: Apr 10, 2026
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
Endocan attenuates LPS-induced alveolar type II cells injury through PI3K/Akt/mTOR pathway
Zekai Wang1, Yulu Zhao2, Ming Luo2
1Department of Pathophysiology, School of Basic Medical Sciences, The Research Institute of Microbiota and Host Inflammation-Related Diseases, Wenzhou Medical University, Wenzhou, China.
Background:
Alveolar type II (AT2) cell injury plays an important role in the pathogenesis of acute lung injury (ALI), but the corresponding treatment options are limited in clinical practice. Endocan has been proved to exert a protective effect in ALI, however, the underlying mechanism remains unclear. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway was found to exhibit beneficial effects in lipopolysaccharide-induced ALI. This study aimed to investigate protective effects of endocan on AT2 cells and the signal pathway in LPS-induced ALI.
Methods:
Pulmonary function testing and hematoxylin-eosin staining were employed to evaluate the effects of endocan on the LPS-induced ALI in mice. Transmission electron microscopy (TEM) analysis, immunofluorescence and Western blot were used to assess the AT2 protection of endocan. Mouse lung epithelial cell line 12 (MLE-12) cells were facilitated to observe the activation of PI3K/AKT/mTOR pathway.
Results:
Endocan administration effectively ameliorated respiratory parameters in LPS-challenged ALI mice. TEM revealed that endocan treatment preserved AT2 cell integrity and maintained lamellar body ultrastructure compared to the mice injected LPS only. Western blot analysis showed a higher surfactant protein C expression in endocan-treated mice than that of model group. Moreover, the phosph-PI3K, -AKT, -mTOR levels detected by Western blot were significantly observed upregulated after endocan treatment. However, rapamycin, an mTOR inhibitor, abolished the protective effects of endocan against ALI, indicating this pathway may be critical for its action on AT2 cells. In LPS-treated MLE-12 cells, the Western blot analysis further confirmed that rapamycin suppressed endocan-induced activation of the PI3K/AKT/mTOR pathway, thereby attenuating the protective effects of endocan on MLE-12 cells.
Conclusion:
Endocan protects AT2 cells against ALI through activating PI3K/AKT/mTOR pathway, suggesting its therapeutic potential for AT2 in patients with ALI.
Insights
Endocan protects alveolar type II (AT2) cells from acute lung injury (ALI) by activating the PI3K/AKT/mTOR pathway. This finding suggests endocan as a potential therapeutic agent for ALI patients.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Molecular Signaling
Background:
- Alveolar type II (AT2) cell injury is central to acute lung injury (ALI) pathogenesis.
- Current treatments for ALI are limited, highlighting the need for novel therapeutic strategies.
- Endocan demonstrates protective effects in ALI, but its mechanism of action requires elucidation.
Purpose of the Study:
- To investigate the protective effects of endocan on AT2 cells in lipopolysaccharide (LPS)-induced ALI.
- To determine the role of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway in endocan's protective mechanism.
Main Methods:
- Mice with LPS-induced ALI were treated with endocan, and pulmonary function was assessed.
- Transmission electron microscopy (TEM) and Western blot were used to evaluate AT2 cell integrity and surfactant protein C expression.
- The PI3K/AKT/mTOR pathway activation was examined in mouse lung epithelial cells (MLE-12) using Western blot, with and without the mTOR inhibitor rapamycin.
Main Results:
- Endocan administration improved respiratory parameters and preserved AT2 cell ultrastructure in ALI mice.
- Surfactant protein C expression was upregulated in endocan-treated mice.
- Endocan significantly upregulated phosphorylated PI3K, AKT, and mTOR levels, an effect blocked by rapamycin, confirming pathway involvement.
Conclusions:
- Endocan confers protection to AT2 cells in ALI by activating the PI3K/AKT/mTOR pathway.
- These findings suggest endocan holds therapeutic potential for treating ALI, particularly concerning AT2 cell protection.
More Related Videos
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
01:20The JAK-STAT Signaling Pathway